Recent advances in the chemotherapy of non-small cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 31, Issue 7, 2001, Pages 299-304

  Inoue, Akira ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Chemotherapy; Non small cell lung cancer; Target based therapy

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 7 HYDROXYSTAUROSPORINE; ADVEXIN; ANTINEOPLASTIC AGENT; BORTEZOMIB; CARBOPLATIN; CILENGITIDE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIRUBICIN; ETOPOSIDE; FLAVOPYRIDOL; FR 901228; GEFITINIB; GEMCITABINE; IFOSFAMIDE; INDISULAM; IRINOTECAN; LEFLUNOMIDE; LONAFARNIB; MARIMASTAT; MITOMYCIN C; NAVELBINE; ONYX 015; PACLITAXEL; PLATINUM; PRINOMASTAT; RECOMBINANT HUMAN MONOCLONAL ANTIBODY VASCULOTROPIN; TENIPOSIDE; TIPIFARNIB; TIRAPAZAMINE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITARXIN;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG CHOICE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ELDERLY CARE; GENE SEQUENCE; GENOME; HUMAN; LUNG NON SMALL CELL CANCER; NAUSEA AND VOMITING; NEUTROPENIA; REVIEW; SYMPTOM; TOXICITY; TREATMENT PLANNING;

EID: 0034866490     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hye072     Document Type: Review

References (51)

1. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
2. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: A randomized trial with quality of life as the primary outcome
3. Chemotherapy for advanced non-small cell lung cancer
4. Novel combination chemotherapy in the treatment of non-small cell lung cancer
5. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer
6. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group
7. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology Group
8. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
9. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
10. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group
11. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer
12. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
13. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC)
14. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
15. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
16. Comparison of tirazone (tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): Final results of the international Phase III CATAPULT II Trial
17. Randomized trial comparing cisplatin and irinotecan versus cisplatin and vindesine versus irinotecan alone in advanced non-small cell lung cancer, a multicenter phase III study
18. Randomized multicenter phase III trial of irinotecan and cisplatin versus cisplatin and vindesine in patients with advanced non-small cell lung cancer
19. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project
20. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
21. Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer
22. A randomized phase III trial of the Southern Italy Oncology Group (G.O.I.M.) of mitomycin C plus vindesine and cisplatin (MVP regimen) versus vinorelbine plus cisplatin (PV regimen) in stage III-IV non small cell lung cancer
23. Randomized study of vinorelbine (VRB) or vindesine (VDS) with cisplatin (P) and mitomycin (M) as induction chemotherapy in stage IIIB or IV non-small cell lung cancer (NSCLC) - Final results
24. Randomized pan-European trial comparing paclitaxel/carboplatin versus paclitaxel/cisplatin in advanced non-small-cell lung cancer
25. A randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in untreated advanced non-small-cell lung cancer. A Southwest Oncology Group Trial
26. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
27. A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naïve patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC)
28. Randomized trial comparing cisplatin, gemcitabine and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group
29. Cisplatin-gemcitabine, vs. cisplatin-gemcitabine-vinorelbine, vs. cisplatin-gemcitabine-paclitaxel in advanced non-small-cell lung cancer. First-stage analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial
30. CALGB 9731: Phase II trial of weekly paclitaxel for advanced non-small cell lung cancer
31. Induction chemotherapy with paclitaxel and carboplatin followed by concurrent thoracic radiation and weekly PC for patients unresectable stage III NSCLC: Preliminary analysis of a phase II trial by the Cancer and Leukemia Group B
32. Phase I study of weekly docetaxel (DTX) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) for stage III non-small cell lung cancer (NSCLC)
33. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer
34. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer
35. Phase I/II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC)
36. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in advanced non-small cell lung cancer (NSCLC): A preliminary analysis
37. Docetaxel plus cisplatin versus docetaxel plus gemcitabine chemotherapy in advanced non-small cell lung cancer: A preliminary analysis of a multicenter randomized phase II trial
38. Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small-cell lung cancer (NSCLC); A West Japan Thoracic Oncology Group (WJTOG) study
39. Advanced age alone does not compromise outcome in fit non-small cell lung cancer (NSCLC) patients (Pts) receiving platinum (DDP)-based therapy (TX): Implications of ECOG 5592
40. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
41. Gemcitabine + vinorelbine yields better survival than vinorelbine alone in elderly non-small cell lung cancer patients. Final analysis of a Southern Italy Cooperative Oncology Group phase III trial
42. Gemcitabine plus vinorelbine in non-small cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin
43. Lower recommended dose but not diminished efficacy obtained in elderly patients age 75 years or older in phase I study of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer
44. Cancer chemotherapy in the elderly
45. Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age
46. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
47. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
48. Salvage therapy with gemcitabine (GEM) in pretreated, advanced non-small cell lung cancer (NSCLC)
49. Phase II study of Taxol (T) in patients (PT) with non-small cell lung cancer (NSCLC) who have failed platinum (P) containing chemotherapy (CTX)
50. 2 in platinum-pretreated advanced non-small cell lung cancer (NSCLC)
51. A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC